| 吴迪娜,马士辉.前蛋白转化酶枯草溶菌素9在HER-2阳性乳腺癌组织中的表达及其临床价值[J].安徽医药,待发表. |
| 前蛋白转化酶枯草溶菌素9在HER-2阳性乳腺癌组织中的表达及其临床价值 |
|
| 投稿时间：2025-03-24 录用日期：2025-04-28 |
| DOI： |
| 中文关键词: PCSK9 HER-2 乳腺癌 新辅助治疗 病理完全缓解 免疫组化 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 24 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 评价前蛋白转化酶枯草溶菌素9（PCSK9）在HER-2阳性乳腺癌患者新辅助治疗前的表达情况及其与临床病理特征的关系。方法 回顾性分析2019年7月至2024年4月在中山市人民医院乳腺中心进行新辅助及手术治疗的92例HER-2阳性乳腺癌患者的临床病理资料，对其新辅助治疗前的活检标本进行免疫组织化学染色，检测乳腺肿瘤组织中PCSK9蛋白的表达。结果 PCSK9低表达组pCR率显著高于高表达组（62.5% vs 35.7%，P<0.05）。PCSK9蛋白表达水平与组织学分级、HR状态相关，PCSK9高表达患者中高级别乳腺癌占比较低表达组更高（32.1% vs 7.8%，P<0.05）；PCSK9高表达组HR阳性率显著高于低表达组（82.1% vs 56.3%，P<0.05）；PCSK9蛋白表达水平与年龄、肿瘤大小、肿瘤临床分期、Ki-67增殖指数等无相关性。结论 PCSK9在HER-2阳性乳腺癌中的表达可能是一个重要的预后指标，其低表达的患者能获得更好的新辅助治疗疗效。PCSK9在预测HER-2阳性乳腺癌患者的治疗反应和指导治疗策略方面具有潜在的应用价值。 |
| 英文摘要: |
| Methods The clinicopathological data of 92 patients with HER-2 positive breast cancer who underwent neoadjuvant and surgical treatment in the breast center of Zhongshan People's Hospital from July 2019 to April 2024 were retrospectively analyzed. The biopsy specimens before neoadjuvant treatment and the surgical specimens after neoadjuvant treatment were immunohistochemically stained to detect the expression of PCSK9 protein in breast tumor tissues. Results The PCR rate in low PCSK9 expression group was significantly higher than that in high PCSK9 expression group (62.5% vs 35.7%, P<0.05). The expression level of psck9 protein was correlated with histological grade and HR status. The proportion of high histological grade in patients with high PCSK9 expression was higher than that in patients with low PCSK9 expression (32.1% vs 7.8%, P<0.05). The positive rate of HR in high PCSK9 expression group was significantly higher than that in low PCSK9 expression group (82.1% vs 56.3%, P<0.05), and had no correlation with age, tumor size, tumor clinical stage, and Ki-67 proliferation index. Conclusions The expression of PCSK9 in HER-2 positive breast cancer may be an important prognostic indicator, and patients with low expression of PCSK9 can obtain better neoadjuvant therapeutic effect. PCSK9 has potential application value in predicting the treatment response of HER-2 positive breast cancer patients and guiding the treatment strategy. |
|
查看/发表评论 下载PDF阅读器 |
| 关闭 |
